CXCL16 and neoplasm: First, targeting the CXCL16-CXCR6 axis may be an effective therapeutic approach, as inhibiting this axis could reduce the recruitment and accumulation of Tc17 cells in the tumor microenvironment, thereby mitigating their immunosuppressive effects.